Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199


BCR/ABL promotes dendritic cell-mediated natural killer cell activation.

Terme M, Borg C, Guilhot F, Masurier C, Flament C, Wagner EF, Caillat-Zucman S, Bernheim A, Turhan AG, Caignard A, Zitvogel L.

Cancer Res. 2005 Jul 15;65(14):6409-17.


Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.

Nieda M, Nicol A, Kikuchi A, Kashiwase K, Taylor K, Suzuki K, Tadokoro K, Juji T.

Blood. 1998 Feb 1;91(3):977-83.


Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.

Cebo C, Voutsadakis IA, Da Rocha S, Bourhis JH, Jalil A, Azzarone B, Turhan AG, Chelbi-Alix M, Chouaib S, Caignard A.

Cancer Res. 2005 Apr 1;65(7):2914-20.


Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells.

Smit WM, Rijnbeek M, van Bergen CA, de Paus RA, Vervenne HA, van de Keur M, Willemze R, Falkenburg JH.

Hum Immunol. 1997 Apr 1;53(2):216-23.


BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.

Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grünebach F, Brossart P.

Cancer Res. 2007 Jun 1;67(11):5489-97.


The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation.

Cebo C, Da Rocha S, Wittnebel S, Turhan AG, Abdelali J, Caillat-Zucman S, Bourhis JH, Chouaib S, Caignard A.

J Immunol. 2006 Jan 15;176(2):864-72.


BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells.

Roger R, Issaad C, Pallardy M, Léglise MC, Turhan AG, Bertoglio J, Bréard J.

Blood. 1996 Feb 1;87(3):1113-22.


Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.

Boissel N, Rousselot P, Raffoux E, Cayuela JM, Soulier J, Mooney N, Charron D, Dombret H, Toubert A, Rea D.

J Leukoc Biol. 2006 Apr;79(4):747-56. Epub 2006 Feb 3.


Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.

Kometani K, Aoki M, Kawamata S, Shinozuka Y, Era T, Taniwaki M, Hattori M, Minato N.

Cancer Res. 2006 Oct 15;66(20):9967-76.


BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs).

Chiorean EG, Dylla SJ, Olsen K, Lenvik T, Soignier Y, Miller JS.

Blood. 2003 May 1;101(9):3527-33. Epub 2003 Jan 2.


Enhancement of antitumor natural killer cell activation by orally administered Spirulina extract in mice.

Akao Y, Ebihara T, Masuda H, Saeki Y, Akazawa T, Hazeki K, Hazeki O, Matsumoto M, Seya T.

Cancer Sci. 2009 Aug;100(8):1494-501. doi: 10.1111/j.1349-7006.2009.01188.x. Epub 2009 May 6.


The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.

Sconocchia G, Lau M, Provenzano M, Rezvani K, Wongsena W, Fujiwara H, Hensel N, Melenhorst J, Li J, Ferrone S, Barrett AJ.

Blood. 2005 Nov 15;106(10):3666-72. Epub 2005 Jul 26.


Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways.

Coudert JD, Scarpellino L, Gros F, Vivier E, Held W.

Blood. 2008 Apr 1;111(7):3571-8. doi: 10.1182/blood-2007-07-100057. Epub 2008 Jan 15.


Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias.

Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L, Cosman D, De Libero G, Wodnar-Filipowicz A.

Blood. 2005 May 1;105(9):3615-22. Epub 2005 Jan 18.


Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.

Mayotte N, Roy DC, Yao J, Kroon E, Sauvageau G.

Blood. 2002 Dec 1;100(12):4177-84. Epub 2002 Aug 1.


The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.

Watanabe T, Hotta C, Koizumi S, Miyashita K, Nakabayashi J, Kurotaki D, Sato GR, Yamamoto M, Nakazawa M, Fujita H, Sakai R, Fujisawa S, Nishiyama A, Ikezawa Z, Aihara M, Ishigatsubo Y, Tamura T.

Cancer Res. 2013 Nov 15;73(22):6642-53. doi: 10.1158/0008-5472.CAN-13-0802.


The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.

El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ, Davies FE, Morgan GJ, Cook GP.

Cancer Res. 2007 Sep 15;67(18):8444-9.


Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells.

Mumprecht S, Claus C, Schürch C, Pavelic V, Matter MS, Ochsenbein AF.

Blood. 2009 May 7;113(19):4681-9. doi: 10.1182/blood-2008-05-156471. Epub 2009 Feb 27.


Supplemental Content

Support Center